Fortress Biotech, Inc. Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)
Fortress Biotech, Inc. (FBIO) reported Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) of -$293.00 thousand for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-06.
Discontinued › Income Statement › Other Income
us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2016-03-15
- Fortress Biotech, Inc. fair value, asset, recurring basis, still held, unrealized gain (loss) for the quarter ending 2014-09-30 was -$293.00K.
- Fortress Biotech, Inc. fair value, asset, recurring basis, still held, unrealized gain (loss) for the quarter ending 2013-09-30 was $0.00.
| Period end | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 0 month | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 1 month | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month |
|---|---|---|---|---|
| 2014-09-30 | $293.00K 10-K · filed 2016-03-15 | -$293.00K 10-Q · filed 2014-11-06 | -$293.00K 10-Q · filed 2014-11-06 | |
| 2014-08-12 | $293.00K 10-K · filed 2015-03-16 | |||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |